Allovir IncNASDAQ:ALVRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7957
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7403/ 12
- Ask / Lots0.7560/ 2
- Open / Previous Close0.7400 / 0.7957
- Day Range
- 52 Week Range
- Volume178,460
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALVR |
|---|---|---|
| 09:32 ET | 1186 | 0.74 |
| 09:38 ET | 2137 | 0.74 |
| 09:50 ET | 100 | 0.73 |
| 09:52 ET | 200 | 0.73 |
| 09:54 ET | 100 | 0.7399 |
| 10:01 ET | 510 | 0.731 |
| 10:03 ET | 200 | 0.7399 |
| 10:06 ET | 100 | 0.731 |
| 10:08 ET | 945 | 0.73955 |
| 10:12 ET | 320 | 0.7348 |
| 10:14 ET | 814 | 0.73475 |
| 10:19 ET | 200 | 0.73475 |
| 10:21 ET | 10062 | 0.74 |
| 10:32 ET | 300 | 0.7301 |
| 10:33 ET | 100 | 0.7353 |
| 10:37 ET | 200 | 0.7404 |
| 10:42 ET | 200 | 0.7404 |
| 10:48 ET | 100 | 0.73525 |
| 10:50 ET | 1000 | 0.7404 |
| 10:51 ET | 468 | 0.73515 |
| 10:53 ET | 300 | 0.7404 |
| 10:55 ET | 100 | 0.7301 |
| 11:00 ET | 1159 | 0.7404 |
| 11:02 ET | 462 | 0.7301 |
| 11:08 ET | 100 | 0.73535 |
| 11:18 ET | 200 | 0.7404 |
| 11:26 ET | 400 | 0.7301 |
| 11:27 ET | 100 | 0.7404 |
| 11:33 ET | 100 | 0.7302 |
| 11:38 ET | 300 | 0.7404 |
| 11:40 ET | 136 | 0.7404 |
| 11:45 ET | 100 | 0.73535 |
| 11:47 ET | 300 | 0.7304 |
| 11:49 ET | 100 | 0.73535 |
| 11:51 ET | 200 | 0.7403 |
| 11:54 ET | 100 | 0.73535 |
| 11:58 ET | 100 | 0.73535 |
| 12:02 ET | 100 | 0.7353 |
| 12:05 ET | 268 | 0.7353 |
| 12:07 ET | 200 | 0.7402 |
| 12:09 ET | 200 | 0.7402 |
| 12:16 ET | 100 | 0.7371 |
| 12:21 ET | 292 | 0.7402 |
| 12:25 ET | 100 | 0.7341 |
| 12:27 ET | 100 | 0.7341 |
| 12:30 ET | 100 | 0.7404 |
| 12:34 ET | 100 | 0.7341 |
| 12:38 ET | 236 | 0.7404 |
| 12:39 ET | 200 | 0.7404 |
| 12:41 ET | 100 | 0.7341 |
| 12:43 ET | 100 | 0.7373 |
| 12:45 ET | 300 | 0.7405 |
| 01:06 ET | 200 | 0.73745 |
| 01:19 ET | 200 | 0.7343 |
| 01:24 ET | 400 | 0.7374 |
| 01:32 ET | 100 | 0.7374 |
| 01:44 ET | 3031 | 0.7405 |
| 01:46 ET | 656 | 0.7353 |
| 01:53 ET | 100 | 0.73745 |
| 01:55 ET | 100 | 0.73745 |
| 01:57 ET | 100 | 0.7406 |
| 02:02 ET | 1218 | 0.7408 |
| 02:04 ET | 135 | 0.7404 |
| 02:06 ET | 300 | 0.7409 |
| 02:09 ET | 100 | 0.741 |
| 02:11 ET | 300 | 0.7427 |
| 02:13 ET | 412 | 0.7444 |
| 02:18 ET | 300 | 0.7449 |
| 02:22 ET | 600 | 0.7454 |
| 02:24 ET | 100 | 0.7346 |
| 02:29 ET | 210 | 0.7476 |
| 02:31 ET | 100 | 0.7476 |
| 02:44 ET | 100 | 0.7489 |
| 02:45 ET | 200 | 0.7486 |
| 02:47 ET | 100 | 0.7489 |
| 02:54 ET | 100 | 0.74175 |
| 02:58 ET | 100 | 0.7487 |
| 03:02 ET | 100 | 0.7491 |
| 03:05 ET | 500 | 0.7491 |
| 03:12 ET | 100 | 0.7421 |
| 03:14 ET | 297 | 0.7495 |
| 03:20 ET | 100 | 0.7494 |
| 03:23 ET | 100 | 0.74215 |
| 03:25 ET | 500 | 0.75 |
| 03:30 ET | 258 | 0.75 |
| 03:36 ET | 1558 | 0.7494 |
| 03:39 ET | 1000 | 0.7501 |
| 03:43 ET | 300 | 0.758 |
| 03:48 ET | 100 | 0.759 |
| 03:50 ET | 317 | 0.759 |
| 03:52 ET | 2721 | 0.737 |
| 03:54 ET | 1346 | 0.778 |
| 03:56 ET | 8530 | 0.7878 |
| 03:57 ET | 6000 | 0.743 |
| 03:59 ET | 7181 | 0.7957 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allovir Inc | 86.5M | -0.5x | --- |
Verastem Inc | 86.1M | -0.8x | --- |
Leap Therapeutics Inc | 85.7M | -0.9x | --- |
PMV Pharmaceuticals Inc | 85.4M | -1.3x | --- |
Maia Biotechnology Inc | 84.3M | -2.5x | --- |
Relmada Therapeutics Inc | 89.0M | -1.0x | --- |
Company Information
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Contact Information
- Headquarters
- 1100 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 617-433-2605
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- David Hallal
- President, Chief Financial Officer, Director
- Vikas Sinha
- Chief Executive Officer, Director
- Diana Brainard
- Co-Founder, Chief Scientific Officer
- Ann Leen
- Chief Accounting Officer
- Brett Hagen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $84.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 115.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-1.65 |
Book Value | $1.28 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
